Weaver C. Barksdale & Associates’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.17M | Sell |
25,353
-278
| -1% | -$12.9K | 1.12% | 50 |
|
|
2025
Q1 | $1.56M | Sell |
25,631
-870
| -3% | -$53K | 1.5% | 39 |
|
|
2024
Q4 | $1.5M | Buy |
26,501
+6,921
| +35% | +$392K | 1.44% | 41 |
|
|
2024
Q3 | $1.01M | Sell |
19,580
-1,038
| -5% | -$53.7K | 0.91% | 56 |
|
|
2024
Q2 | $856K | Sell |
20,618
-503
| -2% | -$20.9K | 0.81% | 60 |
|
|
2024
Q1 | $1.14M | Sell |
21,121
-248
| -1% | -$13.4K | 1.05% | 54 |
|
|
2023
Q4 | $1.1M | Sell |
21,369
-7,291
| -25% | -$374K | 1.07% | 53 |
|
|
2023
Q3 | $1.66M | Buy |
28,660
+4,149
| +17% | +$241K | 1.42% | 43 |
|
|
2023
Q2 | $1.57M | Sell |
24,511
-1,693
| -6% | -$108K | 1.55% | 43 |
|
|
2023
Q1 | $1.82M | Buy |
26,204
+3,252
| +14% | +$225K | 1.7% | 32 |
|
|
2022
Q4 | $1.65M | Buy |
22,952
+643
| +3% | +$46.3K | 1.46% | 44 |
|
|
2022
Q3 | $1.59M | Sell |
22,309
-881
| -4% | -$62.6K | 1.59% | 34 |
|
|
2022
Q2 | $1.79M | Buy |
23,190
+212
| +0.9% | +$16.3K | 1.66% | 34 |
|
|
2022
Q1 | $1.68M | Buy |
22,978
+349
| +2% | +$25.5K | 1.49% | 43 |
|
|
2021
Q4 | $1.41M | Buy |
+22,629
| New | +$1.41M | 1.28% | 53 |
|